Quarterly report pursuant to sections 13 or 15(d)

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v2.4.0.8
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2013
Disclosure Text Block [Abstract]  
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]
           

Estimated

 
   

Carrying Value

   

Fair Value

 

Related party Boston Scientific convertible notes payable 

  $ 4,338,601     $ 3,815,307  

Convertible note payable 

    3,784,500       3,784,500  

Junior secured notes payable 

    210,223       2,015,312  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
   

Quoted Prices in

Active Markets

(Level 1)  

   

Significant

Observable

Inputs (Level 2)  

   

Significant

Unobservable

Inputs (Level 3)  

   

Total Fair

Value  

 
                                 

Derivative liability - warrants 

  $ -     $ -     $ 2,855,367     $ 2,855,367  

Derivative liability - conversion option 

    -       -       -       -  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

As of June 30,

 
   

2013

   

2012

 

Stock options 

    6,754,627       6,111,127  

Warrants 

    12,859,512       6,258,648  

Shares under convertible note agreements 

    542,325       4,287,695  
      20,156,464       16,657,470